Supernus Pharma (SUPN) Reports Q4 Revenue of $155M

Supernus Pharma (NASDAQ: SUPN) reported Q4 revenue of $155 million versus the consensus estimate of $149.42 million.

GUIDANCE:

Supernus Pharma sees FY2022 revenue of $640-680 million, versus the consensus of $707.32 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Akari Therapeutics adds oncology expert Patricia LoRusso to advisory board
• Piper Sandler Reiterates Overweight Rating on Henry Schein (HSIC)